Filing summary
Entity discrepancy: The request identifies Kyntra Bio, Inc., but the supplied Form 10-Q is for FibroGen, Inc. (Nasdaq: FGEN). The summary below reflects the filing provided, for the quarter ended March 31, 2020.
Business context and reporting period
FibroGen is a biopharmaceutical company developing and commercializing therapies for anemia, fibrotic disease, and cancer. Roxadustat was approved in China for CKD-related anemia and in Japan for dialysis patients; pamrevlumab remained in clinical development. The financial statements are unaudited and compare the three months ended March 31, 2020 with the same period in 2019.
Financial results and liquidity
| Metric | Q1 2020 | Q1 2019 / comparison |
|---|---|---|
| Revenue | $24.4 million | $23.9 million; up 2% |
| Development and other revenue | $19.4 million | $23.9 million; down 19% |
| Net product revenue | $5.0 million | None reported |
| Operating expenses | $105.5 million | $72.7 million; up 45% |
| Operating loss | $81.1 million | $48.8 million |
| Net loss | $78.3 million; $0.89 per share | $45.4 million; $0.53 per share |
| Cash from operating activities | $(59.5) million | $22.5 million provided |
Q1 2020 product revenue was from roxadustat sales in China. Cash and cash equivalents were $121.6 million; investments were $414.1 million, for combined cash and investments of approximately $535.7 million at March 31, 2020. Cash, investments, and accounts receivable totaled $594.2 million, down $29.1 million from year-end. Management said available resources were expected to fund anticipated needs for at least 12 months from the filing date, while noting that additional funding may be needed.
Total assets were $824.4 million and total liabilities were $346.7 million. The filing reports finance lease liabilities of $46.9 million and operating lease liabilities of approximately $1.6 million; it does not identify conventional borrowings as a material debt balance. Operating cash use reflected the net loss and working-capital movements, including payment of a $36.3 million accrual and the $50.0 million milestone billing to AstraZeneca. Investing cash inflow largely reflected investment maturities and sales.
Material changes versus the prior comparable period
- Revenue edged higher as $5.0 million of China product sales more than offset a $4.4 million decline in collaboration development revenue, primarily following substantial completion of roxadustat Phase 3 trials.
- Operating expenses rose $32.8 million. SG&A increased $27.4 million, mainly due to FibroGen’s share of AstraZeneca co-promotional expenses in China. R&D rose $4.4 million, including higher pamrevlumab manufacturing and Phase 3 trial costs.
- Net loss widened by $32.9 million, principally due to higher operating expenses. Operating cash flow shifted from $22.5 million provided to $59.5 million used, with significant working-capital effects.
- Roxadustat commercial sales in China began in Q3 2019, making Q1 2020 the first comparable quarter with product revenue.
Outlook, commentary, and risks
- The FDA accepted FibroGen’s U.S. roxadustat NDA in February 2020 and set a PDUFA goal date of December 20, 2020. The Europe MAA filing was expected in Q2 2020; Astellas submitted a supplemental Japan NDA for non-dialysis patients in January.
- FibroGen expected to initiate a Phase 3 pamrevlumab DMD trial in the second half of 2020. It paused near-term enrollment in its IPF Phase 3 trial due to COVID-19 and said the pandemic was slowing enrollment in other trials to varying degrees.
- COVID-19 affected China roxadustat sales, especially in February and March, and clinical-trial enrollment. Management said the quarter’s overall financial results were not significantly impacted relative to prior quarters, but the pandemic’s future effects were uncertain and could affect trials, supply, sales, and liquidity.
- A $130.0 million Europe collaboration milestone asset remained unbilled at quarter-end pending MAA submission. A $50.0 million AstraZeneca milestone was billed after FDA acceptance and received in April 2020; a separate $22.0 million China NRDL milestone was received in Q1.
- FibroGen expected continued losses and rising investment in development and commercialization. Key risks include regulatory outcomes, trial delays, competition, pricing and reimbursement, dependence on Astellas and AstraZeneca, manufacturing and supply constraints, and China operating and regulatory risks.
- Non-cancelable contract obligations totaled $23.5 million, including $11.9 million for roxadustat manufacturing and supply and $11.0 million for future development-program milestones. The filing reported no material legal proceedings or material accruals for active litigation.
Important facts for investors to verify
- Confirm the intended issuer: the supplied filing is FibroGen, Inc., not Kyntra Bio, Inc.
- Check subsequent FDA action and the timing and outcome of the anticipated European MAA submission.
- Track roxadustat China sales, hospital listings, reimbursement, and the effect of COVID-19 on commercial uptake.
- Monitor clinical-trial enrollment and timelines for pamrevlumab and roxadustat programs, including any continued pandemic-related disruption.
- Assess collection and recognition timing for collaboration milestones, especially the $130.0 million Europe milestone asset, and cash burn against management’s stated liquidity horizon.
- Review commercialization costs, partner commitments, supply capacity, and the potential need for additional financing.